NOTCH2 and acute myeloid leukemia: Adamia et al. demonstrated a variant of Notch homolog protein 2 (Notch2-Va) and a variant of FLT3 (FLT3-Va) on AML blast cells [74], representing potential disease markers and targets for new therapies, including CAR T-cell therapy.